New drug AU409 enters first human tests for tough liver cancers

NCT ID NCT05791448

First seen Feb 02, 2026 · Last updated Jun 15, 2026 · Updated 24 times

Summary

This early-phase trial tests a new drug called AU409 in 36 adults with advanced liver cancer or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers also look for early signs that the drug might shrink or slow tumors. This study does not aim to cure the disease but to control it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Los Angeles County-USC Medical Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • USC / Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.